Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study ; volume:118 ; number:12 ; year:2018 ; pages:2188-2188
Thrombosis and haemostasis ; 118, Heft 12 (2018), 2188-2188
- Contributor
-
Schulman, Sam
Gross, Peter L.
Ritchie, Bruce
Nahirniak, Susan
Lin, Yulia
Lieberman, Lani
Carrier, Marc
Crowther, Mark A.
Ghosh, Indy
Lazo-Langner, Alejandro
Zondag, Michelle
- DOI
-
10.1055/s-0038-1675417
- URN
-
urn:nbn:de:101:1-2019042107202495920119
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schulman, Sam
- Gross, Peter L.
- Ritchie, Bruce
- Nahirniak, Susan
- Lin, Yulia
- Lieberman, Lani
- Carrier, Marc
- Crowther, Mark A.
- Ghosh, Indy
- Lazo-Langner, Alejandro
- Zondag, Michelle
Other Objects (12)
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Role of prothrombin complex concentrate in perioperative coagulation therapy
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Role of prothrombin complex concentrate in perioperative coagulation therapy
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
Preparation of a Nonthrombogenic Prothrombin Complex Concentrate
Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Role of prothrombin complex concentrate in perioperative coagulation therapy
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial